Gerhard Ehninger

Research interests

Publications

• Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 –Internal Tandem Duplication Mutation (SORMAIN)

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.03345

• Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30580-1

• BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

  Nature · 2017 · https://doi.org/10.1038/nature24294

• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1614359

• Acute myeloid leukaemia

  Nature Reviews Disease Primers · 2016 · https://doi.org/10.1038/nrdp.2016.10

• Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.67.1982

• Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00362-9

• Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

  Blood Cancer Journal · 2014 · 10.1038/bcj.2014.39

• Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1309533

• Rapamycin extends murine lifespan but has limited effects on aging

  Journal of Clinical Investigation · 2013 · https://doi.org/10.1172/jci67674

• Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300874

• Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.49.9020

• Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.46.4990

• Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1203517

• Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70349-2

• Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)60689-8

• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.234

• Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)62105-8

• Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2010.28.9678

• Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

  Bone Marrow Transplantation · 2008 · 10.1038/bmt.2008.316

• Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.11.6053

• Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)

  Blood · 2006 · 10.1182/blood-2005-08-3167

• Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.03.012

• P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

  Leukemia · 2004 · 10.1038/sj.leu.2403257

• Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro

  Stem Cells · 2004 · https://doi.org/10.1634/stemcells.22-3-377

• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

  Blood · 2002 · https://doi.org/10.1182/blood.v99.12.4326

• Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation

  Blood · 1995 · 10.1182/blood.v86.7.2815.2815

Current projects

No projects listed.